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Introduction: The most common cause of pulmonary hypertension (PH) in patients
is due to left heart failure (HF). Diagnosis of early stages of HF or PH have not
been clearly obvious, recently. Elevated filling pressures in the heart and pulmonary
vascular remodelling is associated with expression changes of the various plasma
levels of biomarkers.
Purpose: To assess the plasma levels of HF biomarkers on a new rodent model of
HF induced by the left ventricle pressure-overload which leads to the development
of reactive PH consist of pulmonary vascular remodelling.
Methods: The left heart failure was induced by pressure overload in adult male
Wistar rats by inserting a polyethylene tubing into aorta trough the right carotid
artery. Three weeks later experimental animals were studied (the group E, n=6)
and compared to the controls (n=6). Serial venous blood samples were taken
from both experimental groups to determine levels of biomarkers involved in
pathophysiology cardiac and vascular remodelling: Troponin I, N-proBNP, Copeptin,
Apelin, Endostatin, Asymmetric dimethylarginine (ADMA), Growth/differentiation
factor 15 (GDF-15), Ceruloplasmin and Cystatin-C. The biomarker levels were
assessed by ELISA method.
Results: The left ventricle end-diastolic pressure was elevated in the group E
(1.34±0.07 mmHg vs. 0.41±0.13 mmHg in the controls; p<0.0001). Mean pulmonary
arterial blood pressure measured by catheterization was increased 22.9±0.7 mmHg
compared to the controls 16.9±1.0 mmHg; p<0.05. Weight of the right ventricle
relative to body weight was 5.5±0.3.10-4 compared to the controls 4.6±0.2.10-4;
p<0.05. In lung histology, 74% of small pulmonary vessels had muscularized media
(24% in controls; p<0.01).
Elevated blood plasma levels of biomarkers in the group E compared to the controls
were found in: NT-proBNP (671.8±61.2 pg.mL-1 vs. 450.3±47.5 pg.mL-1; p<0.05;
respectively) and Copeptin (251.9±41 pg.mL-1 vs. 141.3±10.1 pg.mL-1; p<0.05;
respectively). Significantly decreased blood plasma levels of biomarkers in the
group E compared to the controls were found in the values of Apelin (4.0±0.09
ng.mL-1 vs. 4.3±0.05 ng.mL-1; p<0.05; respectively) and ADMA (12.1±0.5 mg.mL-1
vs. 15.3±0.8 mg.mL-1; p<0.05; respectively). We found no significant changes in
the blood plasma levels compared to the controls in the values of TnI, GDF-15,
Endostatin, Cystatin-C and Ceruloplasmin.
Conclusion: We develop a brand new rodent model of PH accompanied with pul-
monary vascular remodelling induced by left HF. Presented experimental model
was associated with increased concentration of biomarker of cardiac remodelling:
NT-proBNP and Copeptin and with decreased level of biomarkers that have protec-
tive effect against vascular remodelling: Apelin and ADMA.
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Background: Coronary artery disease (CAD) is the leading cause of death world-
wide, and percutaneous coronary intervention with stenting the most widely
performed procedure to treat CAD. However, current stent monitoring tech-
niques are invasive and/or ionizing. Microwave spectrometry (MWS) may provide
a non-invasive, non-ionizing and cost-effective alternative capable of detecting
stent-related pathologies before they cause fatal heart failure.
MWS response to monitor stent status
Purpose: To develop a new MWS-based technology to monitor coronary stents in
an in vivo swine model.
Methodology: First, using a new MWS device, an in vitro experiment was carried
out to demonstrate: (1) the ability of detecting the presence of a stent and (2) stent
fractures (SF). To that end, an intact stent was distanced 3, 7, 11 and 15 mm from a
MWS near-field probe in open-air conditions. Afterwards, three identical stents were
piecemeal cut to emulate type I, II and III SF at different fractions of the stent’s length
(l): l/5, l/3 or l/2. Additionally, the stent was measured in a phantom substance, to
simulate in vivo conditions: it was distanced from 0 to 40 mm in steps of 5 mm.
Likewise, a pair of MWS far-field antennas measured the stent at 10, 20, 30 and
40 mm.
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Background: Heart failure (HF) contemporary management has significantly
improved over the past two decades leading to better survival. How application of
the contemporary HF management guidelines affects the risk of death estimated
by available web-based risk scores is not elucidated.
Objective: To assess changes in mortality risk prediction after a after a 12-month
management period in a multidisciplinary HF Clinic.
Methods: Out of 1.689 consecutive patients with HF admitted at our ambulatory
HF Clinic from May 2006 to November 2018, those who completed one year
follow-up were considered for the study. Patients without NTproBNP measurement
or with more than 3 missing variables for risk estimation were excluded. Three
contemporary web-based HF risk scores were evaluated: MAGGIC-HF, Seattle HF
Model (SHFM) and the Barcelona Bio-HF Calculator containing NTproBNP (BCN
Bio-HF). Risk of all-cause death at one year and at 3 years were calculated at
baseline and re-evaluated after 12-month management in a multidsisciplinary HF
Clinic. Wilcoxon paired data test was used to compare changes in mortality risk
estimation over time and test equality of matched pairs for comparing estimated
change among tools. 442 patients used to derive the Barcelona Bio-HF Calculator
were excluded for discrimination purposes.
Results: 1.157 patients were included (age 65.7 ± 12.7 years, 70.4% men). A
significant reduction in mortality risk estimation was observed with the three HF risk
scores evaluated at 12-months (Table). The BCN Bio-HF model showed significantly
different changes in risk estimation, fact that indeed was partnered with numerically
better discrimination. AUC at 1 and 3 years, respectively, were: BCN Bio-HF (0.773
and 0.775), MAGGIC HF (0.686 and 0.748) and SHFM (0.773 and 0.739).
Conclusions: The three web-based risk scores evaluated showed a significant
reduction in mortality risk estimation after 12 month management in a multidisci-
plinary HF Clinic. The BCN Bio-HF score showed higher reduction in estimated
risk, together with better discrimination, likely because it incorporates contemporary
treatment and use of biomarkers.
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Background: Pulmonary rehabilitation (PR) is a complete intervention based on an
evaluation of the patient and followed by adapted therapies for education, behav-
ior change, and pulmonary physiotherapy to optimize the patient’s condition and to
improve: physical capacity, quality of life, dyspnea and fatigue, characteristic symp-
toms in Heart Failure (HF), and Chronic Obstructive Pulmonary Disease (COPD).
However, there is evidence of the low exercise tolerance, and worse functional class
affect their muscle functionality and prognosis. Therefore, PR has beneficial effects
on these aspects. Despite this, no studies are demonstrating the benefit in patients
with concomitant HF and COPD.











































*Median (IQR) values. #Wilcoxon paired data test.
Groups differences
Before PR After PR p








Handgrip strength (kg) 28.03± 7.19 29.22± 6.88 0.213
Phase angle 5.59± 0.66 5.63± 0.65 0.625
PR: Pulmonary Rehabilitation
Objective: To evaluate the effect of PR on exercise tolerance and functional class
in patients with HF and COPD concomitant.
Materials and Methods: In a pilot clinical trial patients older than 40 years with
a confirmed diagnosis of HF and COPD concomitant were included.Patients with
cancer and exacerbations less than 3 months were excluded. They got into a
pulmonary rehabilitation program 3 times a week for 3 months. Exercise tolerance
was evaluated by the 6-minute walk test. A paired t-student and Wilcoxon was
performed.
Results: Fourteen subjects were included, age was 67.86 ±9.34 years, 86.7% were
men, 40% had obesity, 33.3% diabetes, 20% OSAS, and 60% hypertension. After
the intervention, exercise tolerance increases 64.72 ± 105.29 meters, p = 0.038.
Besides, improved the functional class (p = 0.004). The rest of the variables, there
was no significant difference.
Conclusions: The PR improves clinical status in patients with both pathologies.
However, studies involving these types of patients are not carried out. Therefore a
program PR in patients with concomitant HF and COPD improves tolerance to the
exercise of quality of life and probably the prognosis.
Chronic Heart Failure: Rehabilitation
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Introduction: Decompensated Heart Failure (HF) patients are often characterized
by functional dyspnea, fatigue, edema, functional dependence and impairment of
performance in activities of daily living.
Aerobic exercise training (AET) is a well establish cardiac rehabilitation intervention
which improves symptoms, promotes the functional capacity and even increase
exercise tolerance. Although the benefits, exercise is not yet validated for inpatients
during the phase of stabilization.
Purpose: To evaluate the feasibility and safety of an AET program for patients
admitted due to decompensated HF: ERIC-HF (Early Rehabilitation in Cardiology
– Heart Failure) program
Methods: Pilot randomized controlled single-blind trial Patients are randomized in
training group (TG) or control group (CG). Data include cardiovascular history, HF
history and two functional tools: London Chest of Daily Living Activities (LCADL)
and Barthel Index (BI). TG patients performed the ERIC-HF program twice a day for
5 days per week. ERIC-HF program is a supervised AET program, with increasing
levels of intensity, divided into 5 stages (respiratory training, cycloergometer training,
gait training and climbing stairs, for progressive duration periods). Vital signs were
evaluated before and immediately after the exercise, as well as the Borg Modified
Perceived Exertion. CG patients performed physical activity in accordance with the
guidelines available for inpatients, always supervised too. A six-minute walking test
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(6MWT) was performed as soon as patients are able to do it. At discharge, all patients
perform another 6MWT, as so as evaluation of LCADL and BI.
Results: 114 patients were randomized (64 in TG and 50 in CG) with an average
of age of 72 (±9) years old, 70 are male, 82% are in NYHA class III. At admission,
both groups have the same level of functional dependence according to LCADL
(31 vs 32) and Barthel (73 vs 73) scores. TG patients performed 932 sessions of
exercise, with an average of 17 sessions each, for 15 (±9) days of hospitalization.
There is a difference of 83 meters between the two 6MWT performed by TG patients,
which demonstrates clinical significance. At discharge, TG patients presented lower
LCADL score (12 vs 16, p=0.006), higher BI (98 vs 92, p=0.038) score and a 64
meters difference on the 6MWT (p=0.0032) which represents a better functional
capacity. There were absence of adverse events like falls, precordial pain, malignant
arrhythmias and worsening of clinical state
Conclusions: ERIC-HF program demonstrated, in this sample of patients, to be safe
and to promote functional capacity. We can also infer that probably AET is safe and
viable, for this kind of patients, related to the absence of adverse events. No other
study of our knowledge has demonstrated this findings.
Heart Transplantation
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Background: Performing heart transplantation (HT) in patients receiving oral antico-
agulation (OAC) implies a bleeding risk, as normalizing the International Normalized
Ratio (INR) with vitamin K takes up to 24 hours. Our aim was to study the efficacy
and safety of Prothrombin Complex Concentrate (PCC) for reversing the INR prior
to HT.
Methods: Retrospective study of patients undergoing elective HT from 2009 to
March 2017 in two institutions. We designed a protocol for patients on OAC based
on switching to Acenocoumarol when listed for HT and the administration of vitamin
K and PCC at a dose of 25 UI/kg prior to intervention. Among patients with and
without OAC we compared the use of blood products, major bleeding, thrombotic
events and survival.
Results: 140 patients were included in the study (median age 60.5 years, 24.3%
females). 74 patients received OAC and had a median INR of 2.44 on admission
to hospital. After applying the PCC protocol, median INR in this group was 1.43.
Results are summarized on table 1. Major bleeding was found in 41.9% of the OAC
group and 42.4 % in the no OAC group (p=0.949). Patients listed for HT on OAC
underwent re-sternotomy more frequently than non-OAC patients (13.5% vs 1.5%,
p= 0.008). Survival to discharge was similar in the two groups (91.9% in the OAC
group vs 87.9% in the non-OAC group, p=0.429). Requirements for fresh frozen
plasma were higher among the OAC patients (p < 0.001). One patient in each group
had a ischemic stroke, with no other thrombotic complications.
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Primary graft failure n(%) 11 (16.7) 13 (17.6) 0.987
CVVHD n(%) 16 (24.2) 13 (17.6) 0.331
Days in ICU 6 (4-11.5) 6 (4-11) 0.629
In-hospital mortality
n(%)
8 (12.1) 6 (8.1) 0.429
PRC 72 hours after HT 4 (2-6) 4 (2-6.5) 0.891
Platelets 72 hours after
HT
2 (0-2) 1 (0-3) 0.961
FFP 72 hours after HT 1 (0-1) 2 (1-4.5) <0.001
Outcomes in patients treated and not treated with OAC and requirements of blood
products. Cuantitative variables are represented by median and interquartile range.
CVVHD: Continuous venovenous hemodialysis. FFP: Fresh frozen plasma. ICU:
Intensive care unit. NE: Norepinephrine. OAC: Oral anticoagulants. OR: Operation
room. PPRC: Packed red cells.
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Background: The influence of the external counterpulsation (ECP, EECP) on patients
with diastolic dysfunction of the left ventricle (LV) is unclear. We aim to determine
whether external counterpulsation therapy improves echocardiographic parameters
in these patients.
Methods: We studied 57 patients with stable coronary artery disease undergoing
one course of external counterpulsation therapy. The average age of the patients
was 63.07 ± 7.44 years (there were 43 (75.4%) male and 14 (24.6%) women).
All patients divided into two groups: patients with diastolic dysfunction of the left
ventricle (E/e’ ratio>14, total 15 patients, main group) and control group (E/e’<=14,
total 42 patients). The mean age of the patients included in the main and control
groups was 64.20±5.93 and 62.67±7.93 years (p=0.36). All patients treated with one
course of ECP (EECP) treatment (33.26±3.60 and 32.85±4.56 sessions, p=0.38).
Results from echocardiographic examinations after the treatment in these groups
were compared. Echocardiographic assessment included evaluation of the chamber
size, chamber volume, ejection fraction of the left ventricle (LV) by 2D and Doppler
measurements.
Results: Echocardiographic parameters for main and control groups before treat-
ment: the diastolic diameter of the LV (cm): 5.65±0.97 and 5.20±0.62 (p=0.0913);
the end-diastolic volume of the LV (ml): 93.53±28.38 and 75.45±25.13 (p=0.0163);
LV stroke volume (ml): 48.57±11.47 and 43.02±10.64 (p=0.1471); LV ejection frac-
tion (%): 52.83±10.12 and 59.11±9.53 (p=0.0340); the volume of the left atrium
(ml): 73.25±22.79 and 57.86±20.60 (p=0.0229); tissue Doppler velocity of the mitral
annulus (e ’, cm/s): 5.89±1.18 and 7.43±1.50 (p=0.0006); E/e’ ratio: 18.85±3.40
and 9.69±1.95 (p<0.0001). Echocardiographic parameters for the main and con-
trol groups after treatment: the diastolic diameter of the LV (cm): 5.53±0.85 and
5.15±0.57 (p=0.1879); the end diastolic volume of the LV (ml): 92.91±31.29 and
75.15±22.78 (p=0.0536); LV stroke volume (ml): 50.77±11.49 and 47.01±11.24
(p=0.2612); LV ejection fraction (%): 56.81±10.50 and 64.06±7.67 (p=0.0088);
the volume of the left atrium (ml): 60.84±16.20 and 55.77±17.53 (p=0.2388); tis-
sue Doppler velocity of the mitral annulus (e’, cm/s): 6.15±1.11 and 7.73±1.90
(p=0.0037); E/e’ ratio: 15.97±5.39 and 10.08±2.81 (p<0.0001). Statistically signif-
icant changes between two groups noted for the left atrium volume: decrease in
12.41±16.33 ml and 2.09±13.72 ml (p=0.0124) in both groups, and for E/e’ ratio:
decrease in -2.87±3.94 in the main group and increase in 0.39±2.12 in the control
group (p=0.0003).
Conclusion: ECP treatment was associated with a decrease in the left atrium volume
and E/e’ ratio in patients with diastolic dysfunction of the left ventricle.
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